Solstice Raises $21M in Series A Funding Led by Transformation Capital

The round also saw participation from Twelve Below, Virtue Ventures and others. The raise brought the total amount to approximately $25M.

The company plans to use the funds to speed up go-to-market expansion, continue product development, and grow its product and customer-facing teams.

Solstice combines AI technology with in-house experts to replace traditional workflows used by marketing agencies, regulatory teams, and internal marketers. The platform analyzes a brand’s clinical data, FDA documents, and approved research to understand the product and quickly create digital campaigns, ads, and communications for patients and healthcare providers.

Each piece of content is reviewed using Solstice’s proprietary pharmaceutical marketing AI models along with human experts to ensure quality and compliance. The platform also predicts how likely content is to receive MLR approval before it reaches regulatory review teams. Solstice then tracks content performance to identify the best-performing materials and create new content that improves physician and patient engagement, helping pharmaceutical companies produce compliant marketing content faster and more effectively.

Solstice helps customers launch campaigns 12 times faster than traditional agencies, allowing content to move from concept to MLR submission in less than 48 hours and become market-ready in about 10 days. Teams using the platform create nearly three times more high-quality content each quarter while reducing the average number of MLR review rounds per asset from 3.2 to 1.2.

"Bringing a new drug to market is one of the most valuable and heavily regulated processes in healthcare, yet the commercialization workflow has barely changed in decades," said Vinay Shah, Partner and Founding Team Member at Transformation Capital. "Solstice is using AI to fix that — helping pharma brands move faster without compromising compliance. Customers are already seeing real results via faster reviews and meaningful cost savings. We're thrilled to lead this round and partner with the Solstice team."

"Before Solstice, getting a single marketing asset through MLR could take weeks of back-and-forth that delayed launch and healthcare provider outreach," said Kristine Saffrin, marketing director, Alexion Pharmaceuticals. "Now we move from draft to approved in days, which means our team can actually deliver on the personalization and pace a modern brand demands."

Read More:Triomics Raises $22M in Series B Funding Led by Battery Ventures

"We built Solstice to help life sciences teams bring therapeutics to market faster by unifying content creation, medical review and performance insights in a single AI-native system that generates beautiful content, grounds every claim in clinical evidence before MLR review and measures what content will actually move the needle in driving physician and patient action," said Aris Saxena, co-founder and CEO of Solstice. "Our customers used to run three review cycles per asset; now they run one or two at most, and content that used to take months goes out in 10 days. Most importantly, they create more personalized, higher-performing content that helps them compete in increasingly crowded biopharma markets."

About Solstice

Founded by Aris Saxena and Yiwen L., Solstice is an AI-powered marketing platform for pharmaceutical brands. The company combines AI technology with in house experts to create, review, and launch compliant marketing content faster, replacing the traditional workflow between agencies, regulatory teams and internal marketers.

Read More:Countable Labs Raises $26M in Funding Led by ARCH Venture Partners